Mechanics Bank Trust Department Maintains Holdings in Merck & Company, Inc. (MRK)
Mechanics Bank Trust Department held its position in Merck & Company, Inc. (NYSE:MRK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,619 shares of the company’s stock at the close of the second quarter. Mechanics Bank Trust Department’s holdings in Merck & were worth $2,283,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Cascade Investment Advisors Inc. grew its stake in Merck & by 15.5% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after buying an additional 232 shares in the last quarter. Vigilant Capital Management LLC grew its position in shares of Merck & by 16.7% during the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after purchasing an additional 250 shares in the last quarter. Harbour Capital Advisors LLC purchased a new position in shares of Merck & during the 1st quarter valued at $127,000. Pinnacle Bank purchased a new position in shares of Merck & during the 1st quarter valued at $152,000. Finally, Mascoma Wealth Management LLC grew its position in shares of Merck & by 8.2% during the 2nd quarter. Mascoma Wealth Management LLC now owns 2,474 shares of the company’s stock valued at $159,000 after purchasing an additional 187 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.
A number of research analysts have recently commented on the stock. BMO Capital Markets restated a “buy” rating and set a $72.00 price target on shares of Merck & in a research report on Friday, September 8th. Credit Suisse Group restated an “outperform” rating and set a $74.00 price target (down from $75.00) on shares of Merck & in a research report on Tuesday, September 5th. Cowen and Company restated a “hold” rating and set a $70.00 price target on shares of Merck & in a research report on Friday, September 1st. Jefferies Group LLC restated a “sell” rating and set a $52.00 price target on shares of Merck & in a research report on Sunday, August 20th. Finally, HSBC Holdings plc upgraded shares of Merck & from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $70.00.
COPYRIGHT VIOLATION WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/mechanics-bank-trust-department-maintains-holdings-in-merck-company-inc-mrk/1576276.html.
Merck & Company, Inc. (NYSE:MRK) traded down 0.70% during mid-day trading on Wednesday, reaching $65.49. 3,381,076 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $63.52 and a 200-day moving average price of $63.68. Merck & Company, Inc. has a 12-month low of $58.29 and a 12-month high of $66.80. The stock has a market capitalization of $178.61 billion, a PE ratio of 35.46 and a beta of 0.81.
Merck & (NYSE:MRK) last posted its earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The company had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. Merck &’s quarterly revenue was up .9% on a year-over-year basis. During the same period last year, the company posted $0.93 earnings per share. Equities research analysts expect that Merck & Company, Inc. will post $3.87 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Thursday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.85%. Merck &’s payout ratio is 76.11%.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.